The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice

Journal of Translational Medicine

Yi-Xin Zeng²  Jian-Chuan Xia²  Nian-Hua Zhang¹  Xia Cheng²  Rui-Qing Peng²  Ya Ding²  Xiao-Shi Zhang²  Ji-Yan Liu² 

[1] State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, China;Department of Biotherapy, Cancer Center, Sun Yat-sen University, Guangzhou, China

关键词: splenic lymphocytes;    mouse tumor model;    CD4+CD25+ T_R cells;   

Others  :  1208511
DOI  :  10.1186/1479-5876-3-5

 received in 2004-11-10, accepted in 2005-01-28,  发布年份 2005

【 摘 要 】

CD4+CD25+ regulatory T lymphocytes (T_R) constitute 5–10% of peripheral CD4+ T cells in naive mice and humans, and play an important role in controlling immune responses. Accumulating evidences show that T_R cells are involved in some physiological processes and pathologic conditions such as autoimmune diseases, transplantation tolerance and cancer, and might be a promising therapeutic target for these diseases.

To evaluate the change of CD4+CD25+ T_R cells in mouse tumor models, CD4+CD25+ subset in peripheral blood and spleen lymphocytes from normal or C26 colon-carcinoma-bearing BABL/c mice were analyzed by flow cytometry using double staining with CD4 and CD25 antibodies.

The proportion of CD4+CD25+/CD4+ in spleen lymphocytes was found to be higher than that in peripheral blood lymphocytes in normal mice. No difference was observed in the proportion in peripheral blood lymphocytes between tumor bearing mice and normal mice, while there was a significant increase in the proportion in spleen lymphocytes in tumor bearing mice as compared with normal mice. Moreover, the proportion increased in accordance with the increase in the tumor sizes. The increase in the proportion was due to the decrease in CD4+ in lymphocytes, which is resulted from decreased CD4+CD25- subset in lymphocytes. Our observation suggests the CD4+CD25+/CD4+ proportion in spleen lymphocytes might be a sensitive index to evaluate the T_R in tumor mouse models, and our results provide some information on strategies of antitumor immunotherapy targeting CD4+CD25+ regulatory T lymphocytes.

【 授权许可】

   
2005 Liu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Feinberg MB, Silvestri G: T(S) cells and immune tolerance induction: a regulatory renaissance? Nat Immunol 2002, 3:215-217.
• [2]Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
• [3]Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune response. Annu Rev Immunol 2004, 22:531-562.
• [4]Shimizu J, Yamazaki S, Sakaguchi S: Induction of Tumor Immunity by Removing CD251CD41 T Cells: A Common Basis Between Tumor Immunity and Autoimmunity. J Immunol 1999, 163:5211-5218.
• [5]Cobbold SP, Nolan KF, Graca L, Castejon R, Moine AL, Frewin M, Humm S, Adams E, Thompson S, Zelenika D, Paterson A, Yates S, Fairchild PJ, Waldmann H: Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunol Rev 2003, 196:109-124.
• [6]Alyanakian MA, You S, Damotte D, Gouarin C, Esling A, Garcia C, Havouis S, Chatenoud L, Bach JF: Diversity of regulatory CD4+T cells controlling distinct organ-specific autoimmune diseases. Proc Natl Acad Sci U S A 2003, 100:15806-15811.
• [7]Nishibori T, Tanabe Y, Su L, David M: Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J Exp Med 2004, 199:25-34.
• [8]Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA: Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004, 199:971-979.
• [9]Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D: Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004, 41:31-37.
• [10]Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004, 200:277-285.
• [11]Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003, 9:606-612.
• [12]Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A: CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003, 98:1089-1099.
• [13]Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H: Increased Populations of Regulatory T Cells in Peripheral Blood and Tumor-Infiltrating Lymphocytes in Patients with Gastric and Esophageal Cancers. Clin Cancer Res 2003, 9:4404-4408.
• [14]Li J, Hu P, Khawli LA, Epstein AL: Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res 2003, 63:8384-8392.
• [15]Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999, 59:3128-3133.
• [16]Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001, 194:823-832.
• [17]Thornton AM, Shevach EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-296.
• [18]Piccirillo CA, Shevach EM: Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001, 167:1137-1140.
• [19]Cederbom L, Hall H, Ivars F: CD4+CD25+ regulatory T cells down-regulate costimulatory molecules on antigen-presenting cells. Eur J Immunol 2000, 30:1538-1543.
• [20]Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV: Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004, 172:4676-4680.
• [21]Godfrey WR, Ge YG, Spoden DJ, Levine BL, June CH, Blazar BR, Porter SB: In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004, 104:453-461.
• [22]Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
• [23]Papiernik M, do Carmo Leite-de-MoraesM, Pontoux C, Joret AM, Rocha B, Penit C, Dy M: T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity. J Immunol 1997, 158:4642-4653.
• [24]Banz A, Pontoux C, Papiernik M: Modulation of Fas-dependent apoptosis: a dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells. J Immunol 2002, 169:750-757.
• [25]Neuner A, Schindel M, Wildenberg U, Muley T, Lahm H, Fischer JR: Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer. Lung Cancer 2001, 34:S79-82.
• [26]de Caestecker MP, Piek E, Roberts AB: Role of transforming growth factor-β signaling in cancer. J Natl Cancer Inst 2000, 92:1388-1402.
• [27]Mocellin S, Wang E, Marincola FM: Cytokines and immune response in the tumor microenvironment. J Immunother 2001, 24:392-407.
• [28]Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
• [29]Chen ZM, O'Shaughnessy MJ, Gramaglia I, Panoskaltsis-Mortari A, Murphy WJ, Narula S, Roncarolo MG, Blazar BR: IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood 2003, 101:5076-5083.